Diarrhea News and Research

Latest Diarrhea News and Research

University of Guelph researchers develop carbohydrate-based vaccine against gut bug

A first-ever vaccine created by University of Guelph researchers for gut bacteria common in autistic children may also help control some autism symptoms.

25 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

Unnecessary use of antibiotics in elderly women in EDs increases risk of unintended consequences

Older adults represent an important and growing demographic in emergency departments across the country, with urinary tract infections being one of the leading causes for ED visits.

23 Apr 2013

GAPPD presents opportunity to meld global, local agendas

"Beyond integration across the two diseases, the [Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea (GAPPD) released by the WHO and UNICEF last week] is an opportunity to meld global and local agendas, giving national governments a comprehensive tool to determine the specific plans, investments, and partners needed to address the unique needs of their countries and achieve the greatest health impact for their citizens," PATH CEO Steve Davis writes in the Huffington Post's "Global Motherhood" blog.

18 Apr 2013

Study suggests strain with Haiti cholera mutations may increase severity of disease

The cholera strain that transferred to Haiti in 2010 has multiple toxin gene mutations that may account for the severity of disease and is evolving to be more like an 1800s version of cholera, reports a new Northwestern Medicine study.

17 Apr 2013

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.

17 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

Luminex's MAGPIX instrument gets FDA approval

Luminex Corporation today announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel.

From Luminex 16 Apr 2013

Gates Foundation's programs complement new global plan to prevent 2M child deaths

John Grove, a senior program officer at the Bill & Melinda Gates Foundation, and Gretchen Meller, a program officer at the foundation, write in the group's "Impatient Optimists" blog, "By addressing [pneumonia and diarrhea] together, the [Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea] goes to the heart of the matter: both diseases are caused by a range of pathogens, and no single intervention alone will eliminate either disease.

15 Apr 2013

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.

11 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Researchers use metagenomics to reconstruct genome sequence of Shiga-toxigenic Escherichia coli

Researchers have been able to reconstruct the genome sequence of an outbreak strain of Shiga-toxigenic Escherichia coli using metagenomics (the direct sequencing of DNA extracted from microbiologically complex samples), according to a study in the April 10 issue of JAMA, a Genomics theme issue.

10 Apr 2013

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Genzyme, a Sanofi company, announced today Argentina's National Administration of Drugs, Food and Medical Technology has approved once-daily, oral AUBAGIO 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis.

9 Apr 2013

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.

8 Apr 2013

FMT treatment improves symptoms in pediatric patients with active ulcerative colitis

A Spectrum Health clinical trial has found that fecal microbial transplantation (FMT) has resulted in the improvement or absence of symptoms in most pediatric patients with active ulcerative colitis.

7 Apr 2013

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.

6 Apr 2013

Diarrhea News and Research

Latest Diarrhea News and Research

University of Guelph researchers develop carbohydrate-based vaccine against gut bug

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

Unnecessary use of antibiotics in elderly women in EDs increases risk of unintended consequences

GAPPD presents opportunity to meld global, local agendas

Study suggests strain with Haiti cholera mutations may increase severity of disease

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Luminex's MAGPIX instrument gets FDA approval

Gates Foundation's programs complement new global plan to prevent 2M child deaths

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

FDA accepts Merck's NDA for NOXAFIL tablets

Researchers use metagenomics to reconstruct genome sequence of Shiga-toxigenic Escherichia coli

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

FMT treatment improves symptoms in pediatric patients with active ulcerative colitis

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in